NRAS Mutations May Require Mutation-Guided Combination Therapies

For years, RAS proteins have been central to cancer biology but difficult to target. The three main types—KRAS, NRAS, and HRAS—function like molecular switches that relay growth signals within cells. When mutated, these proteins can become permanently active, fueling the growth of various cancers such as melanoma, pancreatic, and colorectal cancers.

Despite recent efforts to develop drugs targeting KRAS and HRAS, NRAS remains a tough target. A new study, however, suggests that NRAS-driven cancers might not rely solely on mutant NRAS for growth. Researchers Hyun Lee and colleagues from the Uniformed Services University of the Health Sciences investigated how different NRAS mutations interact with wild-type RAS proteins to sustain cancer signaling.

They found that mutant NRAS proteins do not all behave the same way, depending on their specific mutations. Certain mutations, like those at glycine residues G12X and G13X, can still perform some essential functions on their own. However, other mutations, such as Q61X, are much more dependent on wild-type RAS proteins for activation.

The study also revealed that different NRAS mutations play distinct roles in signaling pathways. Mutant NRAS primarily drives the MAPK pathway, while wild-type HRAS supports the PI3K-AKT pathway. This division of labor creates specific vulnerabilities that could be targeted with tailored drug combinations. For instance, combining inhibitors of both RAS and HRAS showed promising results, especially for Q61X mutations.

In contrast, other NRAS mutations might require inhibitors targeting intermediary proteins like SOS1 or SHP2 to effectively suppress cancer growth. The findings emphasize that a one-size-fits-all approach to treating NRAS-mutant cancers is unlikely to be effective. Instead, mutation-guided combination therapies that consider both the specific NRAS mutation and its wild-type RAS partners could offer a more personalized and successful treatment strategy.